Outsourced Pharma White Papers

  1. Utilizing MAPPs For An Enhanced Assessment Of Immunogenicity 1/4/2024

    Explore how MAPPS demonstrates promise as a valuable tool for comprehensive immunogenicity assessment in therapeutic protein development, contributing to safer and more effective biologics.

  2. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 4/23/2025

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  3. 5 Steps To Design A Microbiological Performance Qualification For Facilities 4/21/2025
    Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
  4. Optimizing DSP Development: Faster Timelines, Lower Costs, And High-Quality Processes 4/8/2025

    The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

  5. Developing Effective Procedures 10/21/2024

    Effective procedure development starts with understanding the purpose and should integrate change management, risk management, and knowledge management to ensure a robust quality system.

  6. Analytical Techniques For Characterization, Release, And Stability Testing 4/28/2025

    Review the analytical considerations for subunit vaccines, vaccines that contain only the antigenic component(s) of a pathogen, and more specifically the assays needed.

  7. Intro To USP <1062> - What It Is And Why You Should Use It 7/20/2023

    Knowing how to use USP <1062> helps manufacturers manage the wide variety of factors that can exacerbate production costs, or result in no product at all.

  8. CHO Cell Lines For Recombinant Protein Production 6/2/2025

    Discover how new strategies in CHO cell line development are driving innovation and transforming the future of biologics manufacturing, from enhanced productivity to improved therapeutic quality.

  9. Setting The Standard For Plasmid DNA Production 10/16/2024

    Discover how Boehringer Ingelheim’s expertise in plasmid DNA manufacturing can propel your innovative therapies forward and transform patient care.

  10. Solid State Hydrogen Deuterium Exchange To Study Antibody Drug Conjugate Stability 10/16/2024

    Discover how this solid-state HDX-MS is being used to revolutionize the prediction of stability for IgG-based Antibody Drug Conjugates and enhance ADC development processes.